Loading…
Neumora Therapeutics, Inc. is projected to rise to $2.07 by 2027, a +11% move from its current price of $1.86. NMRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.77 | $1.86 | $1.95 | -0.07% |
| May 30 | $1.74 | $1.86 | $1.98 | -0.15% |
| May 31 | $1.71 | $1.86 | $2.01 | -0.22% |
| Jun 1 | $1.69 | $1.85 | $2.03 | -0.29% |
| Jun 2 | $1.67 | $1.85 | $2.05 | -0.37% |
| Jun 3 | $1.65 | $1.85 | $2.07 | -0.44% |
| Jun 4 | $1.64 | $1.85 | $2.09 | -0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.64 | $1.85 | $2.09 | -0.51% |
| Week 2 | $1.55 | $1.84 | $2.19 | -1.02% |
| Week 3 | $1.48 | $1.83 | $2.26 | -1.53% |
| Week 4 | $1.43 | $1.82 | $2.33 | -2.03% |
| Week 5 | $1.38 | $1.81 | $2.38 | -2.53% |
| Week 6 | $1.34 | $1.80 | $2.43 | -3.03% |
| Week 7 | $1.30 | $1.79 | $2.48 | -3.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. It develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
The company also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulator (PAM) program for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase products include NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc.
and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Neumora Therapeutics, Inc. (NMRA) operates within the Healthcare sector and is currently ranked 3388 by market capitalization. The stock price is $1.85, and the market capitalization stands at $342.78M.
The overall price outlook reflected in the forecast shows a path of upside over the longer term, even as near-term technical conditions exhibit caution. The stock is positioned within a volatile landscape, and the current price remains near the lower end of the recent trading spectrum.
A major floor 35.5% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 32.8% above — a clean break opens room to run.
A major ceiling 93.0% above — clearing it would confirm fresh momentum.
Key NMRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NMRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.82 | Buy | $1.84 | Buy |
| MA 10 | $1.82 | Buy | $1.86 | Buy |
| MA 20 | $1.99 | Sell | $1.94 | Sell |
| MA 50 | $2.14 | Sell | $2.14 | Sell |
| MA 100 | $2.39 | Sell | $2.24 | Sell |
| MA 200 | $2.19 | Sell | $2.45 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.13 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -39.91 | Neutral |
| Williams %R (14) | -36.67 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.64 | Buy |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 63.33 | Neutral |
| TRIX (15) | -0.81 | Sell |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 46.24 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.86 | Sell |
| ADX (14) | 19.88 | Neutral |
| ATR (14) | 0.08 | Info |
The near-term technical picture shows a bearish tone, with an RSI of 40. The 50-day and 200-day simple moving averages are both $2.19, placing the price below near-term resistance. A key resistance is noted at $2.47, while support sits at $1.67.
The 30-day trading range spans from $1.34 to $2.55, framing a setup that could test either side of that band depending on market momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.63 | $1.86 | $2.35 | 0% | Neutral | |
| $1.53 | $2.07 | $3.02 | +11% | Neutral | |
| $1.67 | $2.37 | $3.65 | +28% | Bullish | |
| $1.91 | $2.82 | $4.53 | +52% | Bullish | |
| $2.25 | $3.46 | $5.76 | +86% | Bullish | |
| $2.00 | $3.20 | $5.48 | +72% | Bullish | |
| $1.84 | $3.03 | $5.34 | +63% | Bullish | |
| $1.97 | $3.36 | $6.07 | +81% | Bullish | |
| $1.97 | $3.47 | $6.41 | +87% | Bullish | |
| $2.65 | $4.80 | $9.05 | +158% | Bullish | |
| $2.34 | $4.91 | $10.10 | +164% | Bullish | |
| $5.30 | $11.77 | $27.08 | +533% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.63 | $1.86 | $2.21 | +0.00% |
| June 2026 | $1.57 | $1.88 | $2.31 | +0.88% |
| July 2026 | $1.44 | $1.74 | $2.19 | -7.28% |
| August 2026 | $1.35 | $1.66 | $2.12 | -4.86% |
| September 2026 | $1.39 | $1.72 | $2.23 | +4.05% |
| October 2026 | $1.39 | $1.73 | $2.28 | +0.66% |
| November 2026 | $1.33 | $1.67 | $2.22 | -3.45% |
| December 2026 | $1.38 | $1.75 | $2.35 | +4.53% |
Click any year to see its month-by-month NMRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NMRA price prediction for 2026 points to an average of $1.86 (low $1.63, high $2.35) — a potential gain of 0% on today's $1.86. A consolidation phase looks the most probable path here.
In 2027, NMRA is projected to trade between $1.53 and $3.02, averaging $2.07 — a potential gain of +11% from today's $1.86. That is up +11% on the projected 2026 average. Price action looks broadly range-bound.
Neumora Therapeutics, Inc.'s 2028 outlook centres on $2.37, within a $1.67 to $3.65 range. That is up +15% on the projected 2027 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, NMRA could reach as high as $4.53, with a base case around $2.82 and support toward $1.91 — roughly +52% from $1.86. Momentum favours further upside here.
Expect NMRA to range from $2.25 to $5.76 through 2030. The $3.46 average target implies a +86% move from current prices. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The NMRA price prediction for 2031 points to an average of $3.20 (low $2.00, high $5.48) — a potential gain of +72% on today's $1.86. Momentum favours further upside here.
In 2032, NMRA is projected to trade between $1.84 and $5.34, averaging $3.03 — a potential gain of +63% from today's $1.86. That is -5% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Neumora Therapeutics, Inc.'s 2033 outlook centres on $3.36, within a $1.97 to $6.07 range. That is up +11% on the projected 2032 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2034, NMRA could reach as high as $6.41, with a base case around $3.47 and support toward $1.97 — roughly +87% from $1.86. Buyers look set to stay in control over this stretch.
Expect NMRA to range from $2.65 to $9.05 through 2035. The $4.80 average target implies a +158% move from current prices. That is up +38% on the projected 2034 average. Momentum favours further upside here.
The NMRA price prediction for 2040 points to an average of $4.91 (low $2.34, high $10.10) — a potential gain of +164% on today's $1.86. Buyers look set to stay in control over this stretch.
In 2050, NMRA is projected to trade between $5.30 and $27.08, averaging $11.77 — a potential gain of +533% from today's $1.86. That is up +140% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NMRA today (≈ 537.634409 NMRA) could be worth
$6,330.13
+$5,330.13 (+533%) by 2050 · US Dollar
Based on the average projected NMRA price of $11.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NMRAwould be worth at today's price.
$1,000 invested in NMRA on May 27, 2025 (≈ 1,430.615163 NMRA) would be worth
$2,660.94
+$1,660.94 (+166.1%) today · 2.66× · US Dollar
Based on a NMRA entry price of $0.699 vs. today's $1.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.72 | $1,081.4 | +8.1% |
| 1 month ago | $2.22 | $837.84 | -16.2% |
| 3 months ago | $3.55 | $523.94 | -47.6% |
| 6 months ago | $2.24 | $830.36 | -17.0% |
| 1 year ago | $0.699 | $2,660.94 | +166.1% |
| All time (2.7y) ago | $17 | $109.41 | -89.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NMRA forecast.
Our base-case forecast reaches $3.70 around 2035.
Implied market cap at $3.70: $685.55M
The year-by-year forecast outlines a multi-year trajectory with clear upside potential alongside ongoing risk. In 2026, the min price is $1.63, the avg is $1.85, the max is $2.37, with a 0% ROI and a Neutral sentiment. By 2027, the avg price is forecast at $2.03 with a max of $3.00 and a 9.9% ROI, remaining Neutral.
The model turns more decisively bullish from 2028 onward, with 2028: avg $2.34 and ROI 26.4%; 2029: avg $2.84 and ROI 53.4%; 2030: avg $3.46 and ROI 86.8%; 2031: avg $3.15 and ROI 70%. The upside continues through 2032–2035, with 2035 showing an avg of $4.79 and ROI 158.7%. The long-range horizon expands to 2040 (avg $4.71, ROI 154.4%) and culminates in 2050 (avg $11.72, ROI 533.4%), all with bullish sentiment.
These figures illustrate meaningful long-term upside, but they are estimates and subject to the usual market and development risks that can affect clinical programs and commercialization timelines.
Tap a question to reveal the answer.
In 2030 the forecast shows min $2.20, avg $3.46, max $5.86 with an 86.8% ROI and a bullish sentiment.
Longer-term forecasts point to bullish sentiment in several years with ROI rising to 53.4% in 2029 and to 533.4% by 2050, but near-term signals range from neutral to bearish. These are estimates, not guarantees.
The forecast max in 2030 is $5.86; later years show max values of $6.08 (2033), $6.41 (2034), $9.25 (2035), and $26.95 (2050). These illustrate potential upside under the forecast assumptions.
The 30-day range is $1.34 to $2.55.
The current price is $1.85 and the market capitalization is $342.78M; the stock is ranked 3388.
Neumora Therapeutics, Inc. Community Discussion
0Share your Neumora Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.